Previous 10 | Next 10 |
PDUFA goal date extension for Nefecon NDA in the U.S. PR Newswire STOCKHOLM , Sept. 14, 2021 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas" or the "Company") (Nasdaq Stockholm: CALTX) (Nasdaq – CALT) , a biopharma company focuse...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
With Labor Day marking the unofficial end of summer, September looks to be a busy month for events impacting pharmaceutical and biotechnology companies. Here's a look at what events to look forward to this month that could impact pharma and biotech stocks. Sept. 3: FDA Cellular, Tissue,...
Shares of Travere Therapeutics remain well below this year's highs despite PROTECT study success. The regulatory update on the FSGS indication of sparsentan has weighed on the share price along with the poor biotech sentiment. While there is uncertainty for the FSGS indication, th...
Calliditas Therapeutics: Interim Report Q2, 2021 Filing of Marketing Authorisation Application on accelerated basis with EMA PR Newswire STOCKHOLM , Aug. 19, 2021 /PRNewswire/ -- "Following the filing for accelerated approval with the FDA in Q1, we filed our ...
Qualigen Therapeutics QLGN -29% on Q2 earnings release Sema4 Holdings SMFR -20% on Q2 earnings release Lightning eMotors ZEV -14% on Q2 earnings release Arcimoto FUV -13% on Q2 earnings release Calliditas Therapeutics (NASDAQ:CALT) -13%. Romeo Power RMO...
Gainers: NanoVibronix (NASDAQ:NAOV) +47%. Enlivex Therapeutics (NASDAQ:ENLV) +20%. GoHealth (NASDAQ:GOCO) +16%. Travere Therapeutics (NASDAQ:TVTX) +16%. Collegium Pharmaceutical (NASDAQ:COLL) +16%. Auddia (NASDAQ:AUUD) +15%. AudioEye (NASDAQ:AEYE) +14%. Cohen & Company (NYSE:COHN) +14%. F...
Calliditas Therapeutics has resolved on a directed share issue in the amount of 2.4 million shares, raising proceeds of approximately SEK 324 million PR Newswire NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STA...
The FDA has granted Fast Track Designation to Calliditas Therapeutics' (NASDAQ:CALT) lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Fast Track status provides for more frequent interaction with the ...
News, Short Squeeze, Breakout and More Instantly...
Calliditas Therapeutics AB Company Name:
CALT Stock Symbol:
NASDAQ Market:
Launch of Phase 3 clinical trial with Nefecon in Japan PR Newswire STOCKHOLM , July 4, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatri...
2024-06-30 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Calliditas provides setanaxib patent update PR Newswire STOCKHOLM , June 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) h...